Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy
✍ Scribed by Yeon-Joo Kim; Heounjeong Go; Hong-Gyun Wu; Yoon Kyung Jeon; Suk Won Park; Seung Hee Lee
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 347 KB
- Volume
- 33
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
We evaluated the predictive significance of 14 reported markers using immunohistochemical study in nasopharyngeal carcinoma.
Methods
Immunohistochemical stainings were done in 38 patients for Met, cyclooxygenase‐2 (COX‐2), nm23‐H1, epidermal growth factor receptor (EGFR), p63, early growth response factor 1 (Egr1), chromosome segregation 1‐like (CSE1L), cathepsin‐D (aspartyl protease), __C‐erb__B2, p53, signal transducers and activators of transcription (STAT3/STAT5), CD138 (Syndecan‐1), and LIN28 with the usual methods.
Results
The median follow‐up time was 30 months (11–83 months). High Met and CD138 expression were statistically significant negative prognostic factors on survival. The expression of Egr1 had a positive prognostic effect on survival. The combined score of these 3 markers, Met plus CD138 minus Egr1, was a strong prognostic factor. The median survival curve was distinctly separated in accord with this combined score. No prognostic value was revealed in COX‐2, nm23‐H1, EGFR, p63, CSE1L, cathepsin‐D, C‐__erb__B2, p53, STAT3, STAT5, and LIN28.
Conclusions
The combined score of these markers could be used to stratify biomolecular risk groups. © 2010 Wiley Periodicals, Inc. Head Neck, 2010